46 completed, 13 recruiting, 12 unknown, 7 terminated. 29 Not applicable, 17 Phase 4, 14 Phase 3, 13 Phase 2, 2 Phase 1.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iDose TR Administration in an Office-Based Surgery Setting iDose TR (travoprost intracameral implant) 75 µg - Open Angle Glaucoma (OAG), Ocular Hypertension (OHT) | Recruiting | Glaukos Corporation | 30 | 2026-05-13 | 2026-09-30 | |
| Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus Riboflavin Ophthalmic Solutions, UV-A Irradiation System - Keratoconus | Phase 4 | Recruiting | Glaukos Corporation | 15 | 2026-05-11 | 2026-06-05 |
| Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 3 | Recruiting | Glaukos Corporation | 510 | 2026-02-17 | 2026-03-30 |
| Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg - Open Angle Glaucoma, Pigmentary Glaucoma | Phase 4 | Recruiting | Jonathon Myers | 20 | 2026-01-05 | 2025-11-14 |
| Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution - Keratoconus | Phase 2 | Recruiting | Glaukos Corporation | 100 | 2025-12-23 | 2026-02-10 |
| Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg Travoprost - Open Angle Glaucoma (OAG), Ocular Hypertension (OH) | Recruiting | Glaukos Corporation | 30 | 2025-12-17 | 2026-02-27 | |
| Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID - Demodex Blepharitis | Phase 2 | Recruiting | Glaukos Corporation | 250 | 2025-12-05 | 2026-02-27 |
| Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 2 | Recruiting | Glaukos Corporation | 110 | 2025-06-12 | 2026-09-17 |
| Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery - Glaucoma, Open-angle, Ocular Hypertension (OHT) | Phase 4 | Recruiting | Glaukos Corporation | 132 | 2025-01-13 | 2026-01-21 |
| Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens Sensor Monitoring with contact lens sensor - Glaucoma Eye | Not applicable | Recruiting | Fundacio Privada Mon Clinic Barcelona | 53 | 2024-10-21 | 2025-03-06 |
| Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Unknown | Glaukos Corporation | 250 | 2023-11-15 | 2023-12-06 |
| Travoprost Intraocular Implant + iStent Infinite Travoprost Intraocular Implant, iStent infinite, Sham procedure - Glaucoma, Open-Angle | Phase 4 | Recruiting | Glaukos Corporation | 150 | 2023-09-14 | 2026-06-02 |
| Travoprost Intraocular Implant in Conjunction With Cataract Surgery iDose TR - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Unknown | Glaukos Corporation | 60 | 2023-09-11 | 2024-06-03 |
| Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma iStent Infinite - Glaucoma | Not applicable | Recruiting | Glaukos Corporation | 245 | 2023-09-01 | 2023-09-28 |
| A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED lufepirsen high dose, Vehicle, lufepirsen low dose - Persistent Corneal Epithelial Defect | Phase 2 | Recruiting | Glaukos Corporation | 84 | 2023-08-17 | 2025-07-24 |
| Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus NXL Energy 1, NXL Energy 2, NXL Energy 3 - Progressive Keratoconus | Phase 1 / Phase 2 | Unknown | Glaukos Corporation | 150 | 2022-03-08 | 2024-07-08 |
| Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3 - Dry Eye Disease, Kerato Conjunctivitis Sicca | Phase 2 | Completed | Glaukos Corporation | 226 | 2022-01-03 | 2023-07-12 |
| Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3 - Presbyopia | Phase 2 | Completed | Glaukos Corporation | 123 | 2022-01-03 | 2023-09-01 |
| Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor iStent Infinite, Competitor Device - Glaucoma, Glaucoma, Open-Angle | Not applicable | Unknown | Glaukos Corporation | 179 | 2021-11-27 | 2024-08-15 |
| Performance of the Travoprost Intraocular Implant Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6 - Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Completed | Glaukos Corporation | 210 | 2021-03-10 | 2024-10-15 |
Showing 20 of 79. Sign in to see all of them.
Glaucoma, Open-Angle (46) · Glaucoma (24) · Ocular Hypertension (17) · Eye Diseases (11) · Keratoconus (11) · Cataract (6) · Myopia (6) · Corneal Diseases (5) · Refractive Errors (3) · Astigmatism (2) · Choroidal Effusions (1) · Dilatation, Pathologic (1) · Dry Eye Syndromes (1) · Exfoliation Syndrome (1) · Hyperopia (1)
Cataract Extraction (8) · Travoprost (5) · Phacoemulsification (4) · Stents (4) · Control Groups (2) · Keratomileusis, Laser In Situ (2) · BID protein, human (1) · Corneal Cross-Linking (1) · Dexamethasone (1) · Dextrans (1) · Flavin Mononucleotide (1) · Lasers (1) · Latanoprost (1) · Lens Implantation, Intraocular (1) · Riboflavin (1)
United States (41) · Armenia (17) · Germany (9) · Spain (8) · Sweden (5) · Austria (4) · Italy (4) · Turkey (Türkiye) (4) · France (3) · Netherlands (2) · Switzerland (2) · Australia (1) · Brazil (1) · Canada (1) · Greece (1)
Jeff Wells, PharmD, MBA (5) · Kerry Stephens, O.D. (5) · Lilit A Voskanyan, MD, PhD (5) · Anders Behndig, MD, PhD (4) · Kerry Stephens, OD (4) · Vineeta Belanger (3) · Jay Katz, MD (2) · Kerry Stephens (2) · Lilit Voskanyan, MD, PhD (2) · Luis G. Vargas, MD (2) · Peter Hersh, MD (2) · Anders Behndig (1)
PMID 22692521, PMID 35943114, PMID 38985408, PMID 39240530, PMID 20207977, PMID 20828829, PMID 22814041, PMID 24452726, PMID 24855336, PMID 29476443, PMID 32021070, PMID 32433094, PMID 35076329, PMID 38060092, PMID 38345710, PMID 39959854, PMID 40126812, PMID 40128494, PMID 41046316, PMID 41832303, PMID 42640621